117 related articles for article (PubMed ID: 36889667)
1. Proteomic profiling and ROC analysis identify CD151 and ELAVL1 as potential therapy response markers for the antiviral drug in resistant TNBC.
Marni R; Malla M; Chakraborty A; Malla R
Life Sci; 2023 May; 320():121534. PubMed ID: 36889667
[TBL] [Abstract][Full Text] [Related]
2. Proteomic Landscape of Exosomes Reveals the Functional Contributions of CD151 in Triple-Negative Breast Cancer.
Li S; Li X; Yang S; Pi H; Li Z; Yao P; Zhang Q; Wang Q; Shen P; Li X; Ji J
Mol Cell Proteomics; 2021; 20():100121. PubMed ID: 34265469
[TBL] [Abstract][Full Text] [Related]
3. Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling.
Kgk D; Kumari S; G S; Malla RR
Chem Biol Interact; 2020 Jan; 315():108872. PubMed ID: 31669320
[TBL] [Abstract][Full Text] [Related]
4. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
5. lncRNA LUCAT1/ELAVL1/LIN28B/SOX2 Positive Feedback Loop Promotes Cell Stemness in Triple-Negative Breast Cancer.
Xia L; Wang H
Breast J; 2022; 2022():7689718. PubMed ID: 35711895
[TBL] [Abstract][Full Text] [Related]
6. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
Luo N; Zhang K; Li X; Hu Y
J Cell Biochem; 2020 Oct; 121(10):4176-4187. PubMed ID: 31922280
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
8. Bufalin attenuates triple-negative breast cancer cell stemness by inhibiting the expression of SOX2/OCT4.
Chen F; Zhu L; Hu J; Jiang S; Liu H; Zheng J; Wang J; Wang F; Li Z
Oncol Lett; 2020 Nov; 20(5):171. PubMed ID: 32934738
[TBL] [Abstract][Full Text] [Related]
9. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
10. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
[TBL] [Abstract][Full Text] [Related]
11. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
12. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
[TBL] [Abstract][Full Text] [Related]
14. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
16. CD151 enrichment in exosomes of luminal androgen receptor breast cancer cell line contributes to cell invasion.
Li D; Lai W; Wang Q; Xiang Z; Nan X; Yang X; Fang Q
Biochimie; 2021 Oct; 189():65-75. PubMed ID: 34157361
[TBL] [Abstract][Full Text] [Related]
17. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
18. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
19. CD151 regulates expression of FGFR2 in breast cancer cells via PKC-dependent pathways.
Sadej R; Lu X; Turczyk L; Novitskaya V; Lopez-Clavijo AF; Kordek R; Potemski P; Wakelam MJO; Romanska-Knight H; Berditchevski F
J Cell Sci; 2018 Oct; 131(21):. PubMed ID: 30257985
[TBL] [Abstract][Full Text] [Related]
20. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
